Prostate-specific antigen in patients with relapsed prostate cancer following endocrine treatment
- Cite this article as:
- Kubota, Y., Yanai, H., Sasagawa, I. et al. International Urology and Nephrology (1996) 28: 349. doi:10.1007/BF02550497
- 14 Views
We assessed the relationship between changes in PSA and prognosis, as a possible reflection of tumour growth in patients who relapse following primary endocrine therapy.
In 8 patients in whom no therapeutic change was attempted after PSA relapse, the PSA level increased exponentially. Their PSA-DT had a close positive relation-ship to the duration of survival after relapse (r=0.79, p=0.02). In 6 patients who received chemotherapy after relapse, PSA-DT between PSA relapse and initiation of chemotherapy also had a relationship to the duration of survival after relapse (r=0.87, p=0.05).
It appears to be reasonable to conclude from these findings that the PSA-DT value is regarded to be a factor associated with prognosis in cases with an exponential increase in PSA after relapse.